Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Kunnafoni nafaman: furakɛli']
["O site web nin labɛnna walisa ka mɔgɔw kalan ani k'u kunnafoni dɔrɔn."]
["Mɔgɔ minw b'o gafew kalan, olu man kan k'u kɛ ka bana dɔw furakɛ."]
['Aw ye aw janto nin na: ɛntɛrinɛti min bɛ ɲiningaliw jaabiw labɛn, a tɛ se ka jatidenw fɔ ka ɲɛ. misali la, bana kɛrɛnkɛrɛnnen dɔ bɛ mɔgɔ minw na.']
["Tuma bɛɛ i ka kan ka ladili ɲini i ka dɔgɔtɔrɔ fɛ wala kɛnɛya baarakɛla dɔ fɛ bana dɔ koo la. I kana ban ka ladili ɲini dɔgɔtɔrɔ fɛ wala ka mɛɛn a ɲinili la sabu i ye koo dɔ kalan site web nin kan. N'i miirila ko bana dɔ be i kan, i ka kan ka teliya ka mɔgɔ wele 911 wala ka taga dɔgɔtɔrɔso la joona joona."]
['Kunnafoniw: sɛbɛkɔrɔ']
["Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (DMCA) ye sariya dɔ ye min b'a to mɔgɔ minw b'u ka gafew sɔrɔ ɛntɛrinɛti kan, olu ka se k'u yɛrɛ lafasa."]
["N'i lanin b'a la ko kunnafoni wala fɛɛn o fɛɛn be sɔrɔ an ka site web kan wala an ka baaraw kan, k'o be i ka sariya tiɲɛ, i (wala i ka lasigiden) be se k'o kunnafoni wala fɛɛn bɔ yen wala k'a bali k'a sɔrɔ."]
['I ka kan ka ci nin ci nin kɛ e-mail fɛ (i ka e-mail lajɛ yɔrɔ nin na)']
["DMCA b'a ɲini ko i ka kunnafoni nunu fara i ka kunnafoni kan: (1) kunnafoni min b'a yira ko i ye baara dɔ kɛ min ka kan ni sariya ye; (2) kunnafoni min b'a yira ko i ye baara dɔ kɛ min ma sariya labato ani kunnafoni wɛrɛw minw b'a to an be se k'o kunnafoni sɔrɔ; (3) i ka ladɛrɛsi, telefɔni nimɔrɔ ani e-mail; (4) i ka seereya dɔ ko i lanin b'a la ko i ye baara min kɛ, ko sariya t'o kɛ."]
["5. i ka sɛbɛ dɔ kɛ ka yira ko i ye tiɲɛn fɔ ani ko joo b'i fɛ ka joo dɔ latanga."]
["O kama, a ka ɲi i k'a ɲini k'a lɔn n'i ka ɲi k'o gafew wala videwo nunu jati k'u ye gafew ye minw labɛnna mɔgɔw ye."]
["N'i ma kunnafoni nunu bɛɛ di, a be se ka kɛ ko i ka ɲinini baara be mɛɛn."]
['Kumaɲɔgɔnya kɛ']
["N'i ka ɲiningaliw wala i ka ladiliw be yen, an ci e-mail fɛ."]
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['A ka kan ka kɛ']
['BioMedLib be baara kɛ ni ɔridinatɛri ye (mansin ka kalan aligoritimiw) ka ɲiningaliw ni jaabiliw dilan ɲɔgɔn fɛ.']
['An ye gafe miliyɔn 35 ta ka bɔ PubMed/Medline ani RefinedWeb kan.']
